



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.

CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

July 17, 2018

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated July 16, 2018

Sub: Clarification _ DRREDDY.

This is with reference to your email dated July 16, 2018, seeking clarification regarding our press release dated July 14, 2018 captioned 'Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film.'

Please find our response to your queries as below:-

Query. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation.

The litigation involves the patent infringement for the generic versions of Suboxone (buprenorphine and naloxone) sublingual film, by the Company named Indivior.

In August 2017, the United States District Court for the District of Delaware found that Dr. Reddy's ANDAs would not infringe any patents held by Indivior. After the non-infringement ruling, Indivior obtained and asserted U.S. Patent No. 9,931,305 (set to expire February 14, 2022) against Dr. Reddy's in another lawsuit.

On June 14, 2018, FDA granted effective approval to Dr. Reddy's ANDAs for its generic version of Suboxone Film. Dr. Reddy's launched its generic products as disclosed in the notification filed with exchanges dated June 15, 2018. In response to a request from Indivior, Judge Kevin McNulty of the U.S. District Court for the District of New Jersey (Newark) issued a Temporary Restraining Order (TRO) that forced Dr. Reddy's to stop its sales as notified in the filing made on June 16, 2018. On June 28, 2018, Judge McNulty held a hearing and then extended the TRO to give himself additional time to consider Indivior's request to block Dr. Reddy's from marketing its generic films during the lawsuit.

On Friday, July 13, 2018, Judge McNulty granted Indivior's request for a preliminary injunction against Dr. Reddy's. Dr. Reddy's as disclosed in its filing on July 14, 2018 confirmed its intent to appeal Judge McNulty's decision granting Indivior's motion and enjoining Dr. Reddy's from making further sales and commercialization of its Buprenorphine and Naloxone Sublingual Film within the United States.

Query. Expected financial implications, if any, due to compensation, penalty etc.


As such there is no direct financial implication relating to compensation and/or penalty. However Dr. Reddy's will not be able to realize financial benefits owing to stop in sales for this product. If Dr. Reddy's ultimately wins, Dr. Reddy's will be reimbursed for potential losses incurred for not being able to sell such Generic products during this time. Further, if Dr. Reddy's loses the case the plaintiff may claim losses on account of Dr. Reddy's sales recorded during the brief period between the launch date and TRO date.

Query. Quantum of claims, if any.

As of this date, no claims or penalties have been levied against Dr. Reddy's.

This is for your information and record.

With regards,


Sandeep Poddar
Company Secretary